Skip to main content
. 2016 Dec 12;8(23):37826–37834. doi: 10.18632/oncotarget.13922

Table 2. Analysis of efficacy in full analysis set.

UFT group (n = 29) OBS group (n = 29) P
PFS
Disease progression or death, No. 25 26
Median (95% CI), months 3.2 (1.4 to 5.0) 3.6 (1.7 to 5.5) 0.752
OS
Death, No. 19 21
Median (95% CI), months 14.2 (11.1 to 17.3 ) 14.2 (8.2 to 20.3) 0.983

Abbreviations: PFS, progression-free survival; OS, overall survival.